Similarly, for patient BR360026, there was no overlap between plasma variants and tumor NGS; nevertheless, the tumor-agnostic WBC-informed approach revealed a tumor-derived KRAS hotspot mutation that was tracked to determine ctDNA molecular response. The gene discussed is KRAS; the disease is neoplasm.